Tornier Nv Ord: (NASD: TRNX)

$16.84

0.01 (0.06%)

Volume 18,333

May 22 11:11 AM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		16.77 - 17.15
	
		52wk Low - High
		14.53 - 23.54
	
		Previous Close
		16.83
	
		Avg. Volume
		243,264
	
		Industry
		MED/DENTAL-SUPP
	
		Market Cap
		702.48 M
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		0.40
	
		PE (Forward)
		0.00
	
		Current Year Est.
		-0.40
	
		Quarterly Earnings ESP 
		0.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Outperform
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		119 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/7/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            NA
                        
                            PEG Ratio
                            NA
                        
                            Current Year Est.
                            -0.40
                        
                            Current Quarter Estimate
                            -0.15
                        
                            Most Accurate Estimate
                            -0.15
                        
                            Earnings ESP 
                            0.00%
                        
                            Next Earnings Report Date
                            08-06-2013
                        
                            EPS Last Year
                            -0.32
                        
                            Expected Earnings Growth
                            22.50%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Tornier N.V. operates as a medical device company offering products that treat orthopaedic conditions of the shoulder, elbow, wrist, hand, ankle and foot. The Company's products are organized in four major categories: upper extremity joints and trauma, lower extremity joints and trauma, sports medicine and orthobiologics, and large joints and other. The upper extremity products include joint replacement and bone fixation devices for the shoulder, hand, wrist and elbow; lower extremity products include joint replacement and bone fixation devices for the foot and ankle; sports medicine and orthobiologics product category includes products used across several anatomic sites to mechanically repair tissue-to-tissue or tissue-to-bone injuries; and large joints and other products include hip and knee joint replacement implants and ancillary products. Tornier N.V. is based in Amsterdam, The Netherlands.   
Full TRNX Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
TRNX Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	-0.15	-0.14	-0.40	-0.09
Number of Estimates	6	6	5	5
Low Estimate	-0.22	-0.20	-0.60	-0.49
High Estimate	-0.11	-0.10	-0.18	NA
Year Ago EPS	-0.07	-0.13	-0.20	-0.40
EPS Growth	-109.52%	-10.26%	-98.00%	77.27%

More TRNX Estimates

Average Earnings Estimates for TRNX

EPS Growth for TRNX

Industry Analysis

Name	Symbol	Previous Close
TORNIER NV	TRNX	16.83
LUXOTTICA ADR	LUX	53.97
ALPHATEC HLDGS	ATEC	1.95
CONMED CORP	CNMD	33.24
COOPER COS	COO	110.99
MWI VET SUPPLY	MWIV	120.38
STERIS CORP	STE	45.99
WEST PHARM SVC	WST	68.41
ALIGN TECH INC	ALGN	38.16
BARD C R INC	BCR	106.71

Sector:Medical>> Industry:MED/DENTAL-SUPP

COMPARE TICKER vs. Its Peers

Zacks Commentary

CONMED 1Q Earnings Beat; Sales Lag

Apr 26, 2013

Bard Beats on 1Q Earnings, Profit Slumps

Apr 24, 2013

Zacks Sell List Highlights: Acacia Research, Williams Partners, Tornier and Fresh Market

Jan 23, 2013

Report for TRNX

May 07, 2013

More TRNX Zacks Commentary

Financials

EPS TTM	-0.32
Sales	278
Net Income	-28
Price/Earnings	NA
Price/Book	1.64
Price/Cash Flow	31.89
Price/Sales	2.46

More TRNX Financials

News

Tornier NV concludes sale of 8.05m ordinary shares, including underwriters' over-allotment option - M2

May 16, 2013

Tornier Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Underwriters' Over-Allotment Option - Businesswire

May 15, 2013

Tornier Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Underwriters` Over-Allotment Option - Benzinga

May 15, 2013

Tornier NV prices public offering at USD16.15 per ordinary share - M2

May 10, 2013

Tornier Announces Pricing of Public Offering of Ordinary Shares - Businesswire

May 9, 2013

Tornier Prices 7M Share Offering at $16.15/Share - Benzinga

May 9, 2013

Tornier Announces Follow-on Offering of 7M Ordinary Shares - Benzinga

May 7, 2013

Tornier Announces Follow-on Offering of Ordinary Shares - Businesswire

May 7, 2013

See All News Stories on TRNX

Broker Recommendations

Current ABR	2.09
ABR (Last Week)	2.18
# of recs in ABR	11
Average Target Price	21.89
Industry Rank by ABR	119 out of 265
Rank in Industry	8 out of 29

More TRNX Broker Recommendations

Username: Password:

Remember me [?]

Forgot Password

New Member